Plain-English translation of NCT07454291 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study of (ENV-101), a new medication being developed to treat a serious lung disease called idiopathic pulmonary fibrosis. Researchers want to understand how moves through your body and whether it can safely be taken alongside the standard medications that patients with this lung condition currently use.
Before this medication can be tested in patients with lung fibrosis, the research team needs to make sure it doesn't cause dangerous interactions when combined with the treatments people are already taking. This study fills that gap by testing those combinations in healthy volunteers first.
You likely qualify if…
You likely don't qualify if…
You will be assigned to one of four groups, and your group will determine what you take and how long you stay at the research clinic (up to 30 days total). Some groups will take the new medication alone or combined with standard lung fibrosis drugs; others will take only standard medications. You'll have blood drawn and other tests done to measure how these medications move through your body. After you leave the clinic, you'll have a follow-up visit about 2 weeks later to make sure you're doing well.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
Australia